Zytiga — Medica
Salivary gland tumors
Initial criteria
- age ≥ 18 years
- used in combination with prednisone
- androgen receptor-positive (AR+) recurrent, unresectable, or metastatic tumor
- used in combination with gonadotropin-releasing hormone (GnRH) analog
Approval duration
1 year